Abstract:Sickle cell disease reflects a complex interplay of genetics, hematology, and clinical symptoms. The intricate pathogenesis of the disease offers a landscape with various targets and treatment options. Anticipated advancements in treatment include combining fetal hemoglobin inducers with other drug classes to improve the efficacy beyond monotherapy. Sickle cell disease (SCD) is an autosomal recessive genetic disorder that occurs due to the point mutation in the β‐globin gene, which results in the formation of sickle hemoglobin (HbS) in the red blood cells (RBCs). When HbS is exposed to an oxygen‐depleted environment, it polymerizes, resulting in hemolysis, vaso‐occlusion pain, and impaired blood flow. Still, there is no affordable cure for this inherited disease. Approved medications held promise but were met with challenges due to limited patient tolerance and undesired side effects, thereby inhibiting their ability to enhance the quality of life across various individuals with SCD. Progress has been made in understanding the pathophysiology of SCD during the past few decades, leading to the discovery of novel targets and therapies. However, there is a compelling need for research to discover medications with improved efficacy and reduced side effects. Also, more clinical investigations on various drug combinations with different mechanisms of action are needed. This review comprehensively presents therapeutic approaches for SCD, including those currently available or under investigation. It covers fundamental aspects of the disease, such as epidemiology and pathophysiology, and provides detailed discussions on various disease‐modifying agents. Additionally, expert insights are offered on the future development of pharmacotherapy for SCD.

Variable frequency evolutionary spectrum

Sickle Cell Disease: From Genetics to Curative Approaches

Current state of gene therapy in sickle cell disease

Current and Future Therapeutics for Treating Patients with Sickle Cell Disease

Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease

[Expectations of established neurologists and general practitioners regarding the psychiatric clinic].

Curative Therapies for Sickle Cell Disease

How I Treat Sickle Cell Disease with Gene Therapy

Role of gene therapy in sickle cell disease

Advancing life: innovative approaches to enhance survival in sickle cell anemia patients

Is Allogeneic Transplantation for Sickle Cell Disease Still Relevant in the Era of Gene Therapy?

Fostering a healthier generation of children with sickle cell disease through advancements in care

Therapeutic Gene Editing for Hemoglobinopathies

Hematopoietic stem cell collection for sickle cell disease gene therapy

Gene therapy in sickle cell disease: Attitudes and informational needs of patients and caregivers

A critical review of therapeutic interventions in sickle cell disease: Progress and challenges

Hematopoietic Stem Cell Transplantation in Sickle Cell Disease: A Multidimentional Review

Cell and Gene Therapy for Anemia: Hematopoietic Stem Cells and Gene Editing

Use of genome-editing tools to treat sickle cell disease

Adsorption kinetics of removal of a toxic dye, Malachite Green, from wastewater by using hen feathers.

Blood Spotlight Review on Gene Therapy for Sickle Cell Disease